HPV-11 and Severe Pediatric Recurrent Respiratory Papillomatosis: Understanding the Link Between Viral Genotype and Disease Severity

Published in Boletín médico del Hospital Infantil de México (October 25, 2025)
Authors: Enrique G. Ortiz-Hernández, Ariadna Vallejo, Diego Guzmán, Melissa León, Natalia Calderón

Recurrent respiratory papillomatosis (RRP) is a rare disease caused primarily by infection with human papillomavirus (HPV) types 6 and 11. Although both viral types are considered low-risk HPV strains from an oncologic perspective, they can cause significant disease in the airway, particularly among children with juvenile-onset recurrent respiratory papillomatosis (JoRRP).

One of the most important questions facing clinicians and families is whether certain HPV types lead to more aggressive disease than others. A recently published study sought to answer that question by examining the relationship between HPV genotype, viral load, and disease severity in pediatric RRP patients.

The findings provide important evidence that HPV-11 may be associated with a more severe clinical course, helping physicians better identify children who may require closer monitoring and more intensive treatment.

Study Abstract

Recurrent respiratory papillomatosis is a condition that occurs mainly in the pediatric population with a rate of 3.62 to 4.3 per 100,000 children. The most common clinical manifestation is dysphonia; however, the disease can progress to more severe forms, generating serious obstruction of the airway. A cross-sectional study was conducted in which patients diagnosed with laryngeal papillomatosis confirmed by histopathological analysis and polymerase chain reaction were included. The genotype of the virus and its viral load were determined through a search in the clinical records, and the clinical and genetic variables of each case were captured through a structured form. A total of 32 patients were enrolled, of which the prevalence of genotype 6 was found in 41% and the same prevalence in the case of genotype 11, with a percentage of coinfection with both subtypes of 18%. Genotype 11 was found to be associated with a greater number of resections (p = 0.004), a higher score on the Derkay scale (p = 0.02) and greater severity when presenting ≥ 4 surgeries per year and/or ≥ 10 total surgeries (p = 0.04). Human papillomavirus genotype 11 showed a greater association with the presentation of greater severity of recurrent respiratory papillomatosis in pediatric patients; therefore, this population is more susceptible to a poor outcome (which increases the demand for medical services), as well as impact on the quality of life of minors.

RRP Task Force Lay Summary

This case series (a cross-sectional observational study) examined 32 children to determine how different strains of the virus affect disease severity. The methods involved using advanced laboratory testing to identify the specific HPV genotype (6 or 11) and measuring the amount of virus present in the tissue. These results were then compared to clinical records, including surgical frequency and anatomical scores. The findings revealed that while HPV-6 and HPV-11 were equally common, children with HPV-11 experienced significantly more aggressive disease. Specifically, those with HPV-11 had higher Derkay scores and were much more likely to require frequent interventions, defined as four or more surgeries per year or more than ten total surgeries. The study concludes that HPV-11 is a clear marker for a more severe clinical course in pediatric patients. This underscores the value of viral genotyping to help clinicians identify high-risk children early, allowing for more personalized management and better preparation for the increased surgical burden and its impact on the child's quality of life.

Why This Study Matters

Not all cases of recurrent respiratory papillomatosis follow the same path.

Some children may require relatively infrequent procedures and maintain stable disease over time. Others experience rapid recurrence of papillomas, repeated surgeries, airway compromise, and significant disruptions to daily life.

Researchers have long suspected that the specific HPV type responsible for infection may influence disease severity. This study provides additional evidence supporting that theory, particularly regarding HPV-11.

Understanding these differences could help clinicians predict disease behavior earlier in a child's treatment journey and better prepare families for what to expect.

Understanding HPV Types 6 and 11 in RRP

The vast majority of RRP cases are caused by:

• HPV Type 6

• HPV Type 11

These viral strains are responsible for the development of papillomas, or wart-like growths, within the respiratory tract.

Although both types can cause significant disease, previous research has suggested that HPV-11 may be associated with:

• Earlier age of onset

• More aggressive disease

• Increased surgical burden

• Greater risk of airway complications

This new study adds further support to those observations.

How the Study Was Conducted

Researchers enrolled 32 pediatric patients with confirmed laryngeal papillomatosis.

Each patient underwent:

• Histopathological confirmation of disease

• Polymerase chain reaction (PCR) testing

• HPV genotyping

• Clinical record review

The investigators examined:

• HPV genotype

• Viral load

• Number of surgeries

• Disease severity

• Derkay scoring

• Clinical outcomes

This approach allowed researchers to compare disease characteristics between children infected with HPV-6 and those infected with HPV-11.

What Is the Derkay Score?

The Derkay score is one of the most widely used tools for assessing RRP severity.

The system evaluates:

• Anatomical extent of disease

• Number of affected airway sites

• Clinical symptoms

• Overall disease burden

Higher Derkay scores indicate more extensive disease and often correlate with greater treatment needs.

Because it provides a standardized way to measure severity, the Derkay score is frequently used in both clinical practice and research studies.

Key Findings

HPV-6 and HPV-11 Were Equally Common

Among the 32 patients studied:

• HPV-6 was identified in 41% of patients

• HPV-11 was identified in 41% of patients

• 18% had coinfection with both types

This finding confirms that both viral strains remain important causes of pediatric RRP.

HPV-11 Was Associated With More Surgeries

One of the most clinically important findings involved surgical burden.

Children with HPV-11 required:

• More surgical resections

• More frequent interventions

• Greater overall treatment intensity

The association between HPV-11 and increased surgical frequency was statistically significant.

For families, this may translate into:

• More hospital visits

• Increased anesthesia exposure

• Greater disruptions to school and daily activities

• Increased emotional and financial stress

HPV-11 Patients Had Higher Disease Severity Scores

Researchers also found that children infected with HPV-11 had significantly higher Derkay scores.

Higher scores indicate:

• More extensive papilloma growth

• Greater airway involvement

• Increased disease burden

This finding suggests that HPV-11 may contribute to more aggressive disease progression than HPV-6.

HPV-11 Was Linked to Severe Disease

The study defined severe disease as:

• Four or more surgeries per year, and/or

• Ten or more total surgeries

Children with HPV-11 were significantly more likely to meet these criteria.

This is particularly important because repeated surgeries remain one of the most challenging aspects of living with RRP.

The ability to identify patients who are more likely to experience severe disease could help clinicians intervene earlier and tailor treatment strategies appropriately.

What About Viral Load?

The investigators also evaluated viral load, which refers to the amount of HPV genetic material present in tissue samples.

While viral load was included in the analysis, the study's most impactful findings centered on HPV genotype rather than viral quantity.

The strongest clinical association identified was between HPV-11 infection and more severe disease outcomes.

Future research involving larger patient populations may further clarify how viral load influences disease progression.

Implications for Patients and Families

The findings from this study reinforce an important reality: RRP is not the same disease for every child.

Knowing a patient's HPV genotype may provide valuable information about expected disease behavior.

For children diagnosed with HPV-11, healthcare providers may consider:

• Closer monitoring

• More frequent follow-up

• Earlier consideration of adjunctive therapies

• Enhanced family education and planning

While genotype alone cannot predict an individual child's future with certainty, it may serve as a useful tool for risk stratification and clinical decision-making.

Implications for Healthcare Providers

The authors highlight the potential value of routine viral genotyping in pediatric RRP.

If future studies continue to confirm these findings, HPV genotyping could become an increasingly important component of comprehensive disease assessment.

Potential benefits include:

• Earlier identification of high-risk patients

• Improved treatment planning

• Better allocation of healthcare resources

• More accurate counseling for families

For a rare disease like RRP, any tool that improves prediction of disease course has significant clinical value.

Why This Research Is Important

This study contributes to a growing body of evidence indicating that HPV-11 is associated with a more aggressive form of recurrent respiratory papillomatosis.

While larger studies are still needed, the findings support the idea that viral genotype matters and that understanding a patient's specific HPV type can provide important insights into disease severity.

For patients, caregivers, and clinicians, this research represents another step toward more personalized approaches to RRP management.

As researchers continue to explore the relationship between HPV biology and clinical outcomes, studies like this may help pave the way for earlier interventions, improved treatment strategies, and better quality of life for children living with RRP.

Key Takeaways

• RRP is primarily caused by HPV types 6 and 11.

• In this study, HPV-6 and HPV-11 were equally prevalent among pediatric patients.

• Children with HPV-11 experienced significantly more severe disease.

• HPV-11 was associated with higher Derkay scores and increased surgical burden.

• Severe disease was more common among children infected with HPV-11.

• Viral genotyping may help identify high-risk pediatric patients earlier.

• The findings support more personalized approaches to RRP management.

Frequently Asked Questions

What is HPV-11?

HPV-11 is one of the primary viral strains responsible for recurrent respiratory papillomatosis and has been associated with more aggressive disease in several studies.

Does HPV-11 mean a child will have severe RRP?

Not necessarily. While HPV-11 is associated with increased disease severity at the population level, individual outcomes can vary considerably.

What is viral genotyping?

Viral genotyping is laboratory testing that identifies the specific HPV strain causing infection.

Why is knowing the HPV type important?

Identifying the HPV type may help clinicians better understand a patient's risk for aggressive disease and guide long-term management.

Can HPV genotype affect treatment decisions?

Potentially. As research advances, genotype information may become increasingly useful in treatment planning and risk assessment.